BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 2007575)

  • 1. Decreased folylpolyglutamate synthetase activity as a mechanism of methotrexate resistance in CCRF-CEM human leukemia sublines.
    McCloskey DE; McGuire JJ; Russell CA; Rowan BG; Bertino JR; Pizzorno G; Mini E
    J Biol Chem; 1991 Apr; 266(10):6181-7. PubMed ID: 2007575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance studies of folylpolyglutamate synthetase-deficient, methotrexate-resistant CCRF-CEM human leukemia sublines.
    McGuire JJ; Heitzman KJ; Haile WH; Russell CA; McCloskey DE; Piper JR
    Leukemia; 1993 Dec; 7(12):1996-2003. PubMed ID: 8255099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines.
    Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR
    Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.
    Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G
    Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.
    Liani E; Rothem L; Bunni MA; Smith CA; Jansen G; Assaraf YG
    Int J Cancer; 2003 Feb; 103(5):587-99. PubMed ID: 12494465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport.
    Matherly LH; Angeles SM; McGuire JJ
    Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folylpolyglutamate synthetase expression in antifolate-sensitive and -resistant human cell lines.
    McGuire JJ; Russell CA
    Oncol Res; 1998; 10(4):193-200. PubMed ID: 9778690
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of bridge region variation on antifolate and antitumor activity of classical 5-substituted 2,4-diaminofuro[2,3-d]pyrimidines.
    Gangjee A; Devraj R; McGuire JJ; Kisliuk RL
    J Med Chem; 1995 Sep; 38(19):3798-805. PubMed ID: 7562910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.
    Miyachi H; Takemura Y; Kobayashi H; Ando Y
    Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potent inhibition of human folylpolyglutamate synthetase by suramin.
    McGuire JJ; Haile WH
    Arch Biochem Biophys; 1996 Nov; 335(1):139-44. PubMed ID: 8914844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of methotrexate sensitivity in human leukemia cell lines by an adenosine triphosphate bioluminescence assay.
    Pinzani P; Carotti S; Gerli A; Pazzagli M; Mazzei T; Mini E
    Anticancer Drugs; 1997 Sep; 8(8):767-77. PubMed ID: 9396621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemical and growth inhibition studies of methotrexate and aminopterin analogues containing a tetrazole ring in place of the gamma-carboxyl group.
    McGuire JJ; Russell CA; Bolanowska WE; Freitag CM; Jones CS; Kalman TI
    Cancer Res; 1990 Mar; 50(6):1726-31. PubMed ID: 2306727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells.
    Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ
    Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM.
    Pizzorno G; Moroson BA; Cashmore AR; Russello O; Mayer JR; Galivan J; Bunni MA; Priest DG; Beardsley GP
    Cancer Res; 1995 Feb; 55(3):566-73. PubMed ID: 7834626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the effect of AG337, a novel lipophilic thymidylate synthase inhibitor, on human head and neck and human leukemia cell lines.
    McGuire JJ; Canestrari JG; Nagel GS
    Int J Oncol; 1999 Dec; 15(6):1245-50. PubMed ID: 10568835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of drug-exposure conditions on the development of resistance to methotrexate or ZD1694 in cultured human leukaemia cells.
    Takemura Y; Kobayashi H; Gibson W; Kimbell R; Miyachi H; Jackman AL
    Int J Cancer; 1996 Mar; 66(1):29-36. PubMed ID: 8608962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thymidylate synthase as a target for growth inhibition in methotrexate-sensitive and -resistant human head and neck cancer and leukemia cell lines.
    McGuire JJ; Magee KJ; Russell CA; Canestrari JM
    Oncol Res; 1997; 9(3):139-47. PubMed ID: 9220499
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin.
    Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y
    Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel 6,5-fused ring heterocyclic antifolates: biochemical and biological characterization.
    McGuire JJ; Bergoltz VV; Heitzman KJ; Haile WH; Russell CA; Bolanowska WE; Kotake Y; Haneda T; Nomura H
    Cancer Res; 1994 May; 54(10):2673-9. PubMed ID: 8168096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impaired polyglutamylation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug.
    Pizzorno G; Mini E; Coronnello M; McGuire JJ; Moroson BA; Cashmore AR; Dreyer RN; Lin JT; Mazzei T; Periti P
    Cancer Res; 1988 Apr; 48(8):2149-55. PubMed ID: 2450647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.